Organon & Co. Stock News

Organon & Co (NYSE:OGN ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Sandra Milligan - Head of R&D Con

Organon & Co reported better-than-expected second-quarter results on Tuesday, helped by strong demand for its women's heath products and biosimilar drugs, sending the healthcare firm's shares up about

Organon, a global healthcare company, is a buy for value and income investors due to its strong growth in biosimilars business and 5.5% dividend yield. Despite a 20% YoY decline in adjusted EBITDA, th

The "Halftime Report" traders give their top picks to watch for the second half.

Organon & Co. OGN, -1.15% and partner Samsung Bioepis Co. Ltd. said Wednesday they have launched their Humira biosimilar Hadlima in the U.S. The move comes after Humira, AbbVie' Inc.'s ABBV, +0.21% rh

Survivorship bias is one of the biggest issues when selecting buy and hold stocks to own for the next 50 years.  What is survivorship bias?

Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis drug Humira, while two other drugmakers entered t

Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis drug Humira, while another drugmaker entered the

Organon & Co. (NYSE:OGN ) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Conference Call Participants Uniden

Organon (OGN) came out with quarterly earnings of $1.08 per share, missing the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.65 per share a year ago.

JERSEY CITY, N.J.

Healthcare stocks have sputtered this year after performing well in 2022. A Barron's screen has identified stocks that are poised to outperform for the rest of the year.

It's too early to say the market has turned the corner, but some analysts suggest that equities could be at the beginning of a bull market. The banking crisis appears to be contained.

Dear Investor:

The company reported fourth-quarter and year-end financials.